logo.png
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
01 juin 2021 07h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University of California San Francisco and...
logo.png
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
25 mai 2021 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...